Wednesday, July 3, 2013

Biotech sector saw increased number of IPOs in Q2, report says

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eAsMCduTtWCjjeqcCidyqVCicNZiGW

July 3, 2013
BIO offers members preferential pricing and complimentary extra biotech-specific features on ShareVault's cutting-edge Virtual Data Room (VDR) technology and Secure Document Sharing services. Learn more and sign up for a free trial.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  Health Care & Policy 
  • FDA turns down high doses of Merck's insomnia drug suvorexant
    Merck & Co. failed to obtain the FDA's approval for higher doses of its investigational insomnia drug suvorexant. The agency sent Merck a complete-response letter saying that safety data don't support the approval of 30- and 40-milligram doses. Suvorexant 10 milligrams should be the starting dose for the majority of patients, the FDA said. Manufacturing studies but not clinical trials will be needed, the company said. PharmaTimes (U.K.) (7/1), MedPage Today (free registration) (7/1) LinkedInFacebookTwitterEmail this Story
  • Bayer, Onyx submit cancer drug Nexavar for U.S., EU approval
    Bayer HealthCare and Onyx Pharmaceuticals have filed regulatory applications with the FDA and the European Medicines Agency for approval to market Nexavar, or sorafenib, as a treatment for locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The applications were based on data from a late-stage trial showing that the drug significantly improved progression-free survival compared with a placebo. Pharmaceutical Business Review Online (7/2) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Protagen turns to diagnostics development after sale of subsidiary
    Venture capital fund Zukunftsfond Heilbronn agreed to acquire Protagen Protein Services, a subsidiary of Protagen. Protagen Protein provides protein analysis and services related to biopharmaceuticals and biosimilars. "The capital injection generated by this transaction is a solid midterm financing opportunity for the Protagen strategy in the area of novel diagnostics, i.e. Dx and CDx, and enables [the company] to start the development of [its] own products for this growing market immediately," Protagen CEO Stefan Müllner said. GenomeWeb Daily News (free registration) (7/2) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • Energy Department commits $4M to Virent
    Virent was awarded a Department of Energy grant worth up to $4 million to further its research on converting plant biomass into fuels. The focus of Virent's three-year undertaking is biomass from loblolly pine trees and corn stover. Virent's is among the four funding grants worth a combined $13 million issued recently by the department to biofuel initiatives. Wisconsin State Journal (Madison) (7/2) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • Save on energy costs through BIO's newest cost-savings program
    BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy suppliers for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  Editor's Note 
  • SmartBrief will not publish Thursday
    In observance of Independence Day in the U.S., SmartBrief will not publish Thursday. Publication will resume Friday. LinkedInFacebookTwitterEmail this Story
  SmartQuote 
Do not go where the path may lead, go instead where there is no path and leave a trail."
--Ralph Waldo Emerson,
American writer


LinkedInFacebookTwitterEmail this Story

 
 
This SmartBrief was created for jmabs1@gmail.com
 
Subscriber Tools
     
Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information

No comments: